Fighting the monster.
Maxmen
Amy
A
D000328:Adult; D017954:Africa South of the Sahara / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000600:supply & distribution / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015897:Comorbidity; D018450:Disease Progression; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D007223:Infant; D011247:Pregnancy; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy* / Q000191:economics / Q000401:mortality
D019380:Anti-HIV Agents; D000995:Antitubercular Agents